Ilmarinen Mutual Pension Insurance Co Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Ilmarinen Mutual Pension Insurance Co increased its stock holdings in Regeneron Pharmaceuticals by 30.7% in the most recent quarter, ending with a total of 14,900 shares valued at approximately $9.45 million.
• Regeneron Pharmaceuticals reported a significant earnings surprise for the last quarter, with $12.89 EPS, which exceeded analysts' expectations of $8.43 EPS, and a revenue of $3.68 billion.
• The company recently announced a quarterly dividend of $0.88, yielding 0.6%, and the stock is currently trading around $556.53.

Ilmarinen Mutual Pension Insurance Co boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 30.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,900 shares of the biopharmaceutical company's stock after acquiring an additional 3,500 shares during the quarter. Ilmarinen Mutual Pension Insurance Co's holdings in Regeneron Pharmaceuticals were worth $9,450,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Marietta Wealth Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after buying an additional 2,501 shares during the period. GAMMA Investing LLC boosted its stake in shares of Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after buying an additional 814,713 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after buying an additional 955 shares during the period. KBC Group NV boosted its stake in shares of Regeneron Pharmaceuticals by 9.4% in the 1st quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock valued at $94,779,000 after buying an additional 12,793 shares during the period. Finally, Lmcg Investments LLC boosted its stake in shares of Regeneron Pharmaceuticals by 231.3% in the 1st quarter. Lmcg Investments LLC now owns 14,481 shares of the biopharmaceutical company's stock valued at $9,184,000 after buying an additional 10,110 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 0.3%

Regeneron Pharmaceuticals stock opened at $556.53 on Wednesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,170.58. The company has a market cap of $58.99 billion, a PE ratio of 14.03, a price-to-earnings-growth ratio of 1.87 and a beta of 0.35. The stock's 50 day moving average price is $563.69 and its 200 day moving average price is $581.96.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the previous year, the business earned $11.56 earnings per share. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.87%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on REGN. JPMorgan Chase & Co. decreased their price objective on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research note on Monday, June 9th. Truist Financial cut their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Raymond James Financial raised Regeneron Pharmaceuticals to a "moderate buy" rating in a research report on Tuesday, September 2nd. Morgan Stanley reissued an "overweight" rating and set a $761.00 target price (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.